When each component of the composite endpoint was separately appraised by multinomial logistic regression, after adjusting for potential confounders, SGLT2-i therapy remained an independent predictor of lower VT/VF occurrence (OR = 0.20; 95%CI 0.04–0.97; p = 0.046) but not for AF occurrence (Table 4), which showed a reduction, without reaching statistical significance (OR = 0.40; 95% CI 0.14–1.14; p = 0.086). The gene discussed is SLC5A2; the disease is atrial fibrillation.